Preview

Transbaikalian Medical Bulletin

Advanced search

LYMPHOTOXIN ALPHA: BIOLOGICAL AND CLINICAL SIGNIFICANCE

https://doi.org/10.52485/19986173_2022_1_44

Abstract

Lymphotoxin α is a one of the tumor necrosis factor family ligand. For almost forty years its pathophysiologic importance as proliferative and inflammatory cytokine was validated. Correlation between some single nucleotide polymorphism and nosological entity was clarified with lyphotoxin’s gene investigation. In clinic it uses in the treatment protocols of rheumatic diseases especially rheumatoid arthritis. Its role in the oncopathological processes is being studied. Lymphotoxin’s system influenced medicines are being researched. Moreover  the  studying  of  genomic  structure  and  biochemical  aspects  under  normal  and  pathological conditions is in process. There are many points of lymphotoxin’s influence on various metabolic ways. The main research results of this cytokine, its genetic structure and its receptors role in pathological conditions and therapeutic approaches, influencing on its system, were observed in the article.

About the Authors

N. E. Garashchenko
Irkutsk state medical university
Russian Federation

664003, Irkutsk, 1 Krassnogo vosstanija St.



I. Zh. Seminskiy
Irkutsk state medical university
Russian Federation

664003, Irkutsk, 1 Krassnogo vosstanija St.



References

1. Aggarwal B.B., Gupta S.C., Kim J.H. (2012). Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood, The Journal of the American Society of Hematology, 119 (3), 651-665.

2. Aggarwal B.B. (2003). Signalling pathways of the TNF superfamily: a double-edged sword. Nature reviews immunology, 3 (9), 745-756.

3. Gubernatorova E.O., Polinova A.I., Petropavlovskiy M.M., Namakanova O.A., Medvedovskaya A.D., Zvartsev R.V., Telegin G.B., Drutskaya M.S., Nedospasov S.A. (2021). Dual Role of TNF and LTα in Carcinogenesis as Implicated by Studies in Mice. Cancers, 13 (8), 1775.

4. Dostert C., Grusdat M., Letellier E., Brenner D. (2019). The TNF family of ligands and receptors: communication modules in the immune system and beyond. Physiological reviews, 99 (1), 115-160.

5. Roach D.R., Briscoe H., Saunders B., France M.P., Riminton S., Britton W.J. (2001). Secreted lymphotoxin-α is essential for the control of an intracellular bacterial infection. Journal of Experimental Medicine, 193 (2), 239-246.

6. Buhrmann C., Popper B., Aggarwal B.B., Shakibaei M. (2017). Resveratrol downregulates inflammatory pathway activated by lymphotoxin α (TNF-β) in articular chondrocytes: Comparison with TNF-α. PLoS One, 12 (11), e0186993.

7. Yokley B.H., Selby S.T., Posch P.E. (2013). A stimulation-dependent alternate core promoter links lymphotoxin α expression with TGF-β1 and fibroblast growth factor-7 signaling in primary human T cells. The Journal of Immunology, 190 (9), 4573-4584.

8. Calmon-Hamaty F., Combe B., Hahne M., Morel J. (2011). Lymphotoxin α stimulates proliferation and pro-inflammatory cytokine secretion of rheumatoid arthritis synovial fibroblasts. Cytokine, 53 (2), 207-214.

9. Piao W., Kasinath V., Saxena V., Lakhan R., Iyyathurai J., Bromberg J. S. (2021). LTβR Signaling Controls Lymphatic Migration of Immune Cells. Cells, 10 (4), 747.

10. Tumanov A.V., Grivennikov S.I., Shakhov A.N., Rybtsov S.A., Koroleva E.P., Takeda J., Nedospasov S.A., Kuprash D.V. (2003). Dissecting the role of lymphotoxin in lymphoid organs by conditional targeting. Immunological reviews, 195 (1), 106-116.

11. Guo S., Zuo Q., Li X., He Y., Zhou Y. (2020). Association between the Lymphotoxin-α A252g Gene Polymorphism and the Risk of Sepsis and Mortality: A Meta-Analysis. BioMed research international, 2020.

12. Shebzukhov Y.V., Kuprash D.V. (2011). Transcriptional regulation of TNF/LT locus in immune cells. Molekulyarnaya biologiya, 45 (1), 47-57. in Russian.

13. Tsai J.F., Chen S.C., Lin Z.Y., Dai C.Y., Huang J.F., Yu M.L., Chuang W.L. (2017). Independent and additive interaction between polymorphisms of tumor necrosis factor α− 308 and lymphotoxin α+ 252 on risk of hepatocellular carcinoma related to hepatitis B. The Kaohsiung journal of medical sciences, 33 (9), 453-457.

14. Li J., Wang Y., Chang X., Han Z. (2020). The effect of LTA gene polymorphisms on cancer risk: an updated systematic review and meta-analysis. Bioscience reports, 40 (5), BSR20192320.

15. Takei K., Ikeda S., Arai T., Tanaka N., Muramatsu M., Sawabe M. (2008). Lymphotoxin-alpha polymorphisms and presence of cancer in 1,536 consecutive autopsy cases. BMC cancer, 8 (1), 1-6.

16. Campbell M.C., Ashong B., Teng S., Harvey J., Cross C.N. (2019). Multiple selective sweeps of ancient polymorphisms in and around LTα located in the MHC class III region on chromosome 6. BMC evolutionary biology, 19 (1), 1-20.

17. Gong L.L., Han F.F., Lv Y.L., Liu H., Wan Z.R., Zhang W., Shi M.B., Pei L.X., Liu L.H. (2017). TNF-α and LT-α Polymorphisms and the Risk of Leukemia: A Meta-analysis. Tumori Journal, 103 (1), 53-59.

18. Um J.Y., An N.H., Kim H.M. (2003). TNF-α and TNF-β gene polymorphisms in cerebral infarction. Journal of Molecular Neuroscience, 21 (2), 167-171.

19. D'Souza W.N., Chang C.F., Fischer A.M., Li M., & Hedrick S.M. (2008). The Erk2 MAPK regulates CD8 T cell proliferation and survival. The Journal of Immunology, 181 (11), 7617-7629. https://doi.org/10.4049/jimmunol.181.11.7617

20. Verma V., Jafarzadeh N., Boi S., Kundu S., Jiang Z., Fan Y., Lopez J., Nandre R., Zeng P., Alolaqi F., Ahmad S., Gaur P., Barry S.T., Valge-Archer V.E., Smith P.D., Banchereau J., Mkrtichyan M., Youngblood B., Rodriguez P.C., Gupta S., Khleif S.N. (2021). MEK inhibition reprograms CD8+ T lymphocytes into memory stem cells with potent antitumor effects. Nature Immunology, 22 (1), 53-66. https://doi.org/10.1038/s41590-020-00818-9

21. Damasio M.P., Marchingo J.M., Spinelli L., Hukelmann J.L., Cantrell D.A., Howden A.J. (2021). Extracellular signal-regulated kinase (ERK) pathway control of CD8+ T cell differentiation. Biochemical Journal, 478 (1), 79-98.

22. Voon D.C., Subrata L.S., Karimi M., Ulgiati D., Abraham L.J. (2004). TNF and phorbol esters induce lymphotoxin-β expression through distinct pathways involving Ets and NF-κB family members. The Journal of Immunology, 172 (7), 4332-4341.

23. Piao W., Xiong Y., Li L., Saxena V., Smith K.D., Hippen K.L., Paluskievicz C., Willsonshirkey M., Blazar B.R., Abdi R., Bromberg J.S. (2020). Regulatory T cells condition lymphatic endothelia for enhanced transendothelial migration. Cell reports, 30 (4), 1052-1062.

24. Husson H., Lugli S.M., Ghia P., Cardoso A., Roth A., Brohmi K., Carideo E.G., Choi Y.S., Browning, J., Freedman A.S. (2000). Functional effects of TNF and lymphotoxin α1β2 on FDC-like cells. Cellular immunology, 203 (2), 134-143.

25. Guo Z., Qiu C., Mecca C., Zhang Y., Bian J., Wang Y., Wu X., Wang T., Su W., Li X., Zhang W., Chen B., Xiang H. (2021). Elevated lymphotoxin-α (TNFβ) is associated with intervertebral disc degeneration. BMC musculoskeletal disorders, 22 (1), 1-10.

26. Shmidt E.A., Berns S.A., Zhidkova I.I., Makeeva O.A., Goncharova I.A., Nagirnyak O.A., Klimenkova A.V., Litvinova M. N., Barbarash, O.L. (2018). Association of a lymphotoxin-α variable site rs1041981 with development of long-term unfavorable outcomes in patients with acute coronary syndrome without ST-segment elevation. Meditsinskaya immunologiya (Russia), 20 (1), 73-84. in Russian.

27. Constanze B., Popper B., Aggarwal B.B., Shakibaei M. (2020). Evidence that TNF-β suppresses osteoblast differentiation of mesenchymal stem cells and resveratrol reverses it through modulation of NF-κB, Sirt1 and Runx2. Cell and tissue research, 381 (1), 83-98.

28. Buhrmann C., Busch F., Shayan P., Shakibaei M. (2014). Sirtuin-1 (SIRT1) is required for promoting chondrogenic differentiation of mesenchymal stem cells. Journal of Biological Chemistry, 289 (32), 22048-22062. https://doi.org/10.1074/jbc.M114.568790

29. Calmon-Hamaty, F., Combe, B., Hahne, M., Morel, J. (2011). Lymphotoxin α revisited: general features and implications in rheumatoid arthritis. Arthritis research & therapy, 13 (4), 1-5. https://doi.org/10.1186/ar3376

30. Marston B., Palanichamy A., Anolik J.H. (2010). B cells in the pathogenesis and treatment of rheumatoid arthritis. Current opinion in rheumatology, 22 (3), 307.

31. Pala O., Diaz A., Blomberg B.B., Frasca D. (2018). B lymphocytes in rheumatoid arthritis and the effects of anti–TNF-α agents on B lymphocytes: a review of the literature. Clinical therapeutics, 40 (6), 1034-1045.

32. Buhrmann C., Shayan P., Aggarwal B.B., Shakibaei M. (2013). Evidence that TNF-β (lymphotoxin α) can activate the inflammatory environment in human chondrocytes. Arthritis research & therapy, 15 (6), 1-14. https://doi.org/10.1186/ar4393

33. Nasonov E.L. (2001). Tumor necrosis factor-α -a new target for anti-inflammatory treatment of rheumatoid arthritis. Sovremennaya revmatologiya, 1, 64-70. in Russian.

34. Karateev D.E. (2014). How real is the long-lasting effect of tumor necrosis factor α inhibitors? Focus on immunogenicity. Sovremennaya revmatologiya, 8 (2), 35-40. in Russian.

35. Karateev D.E. (2009). Etanercept (review of international studies). Nauchno-prakticheskaya revmatologiya, 47 (5), 52-57. in Russian. https://doi.org/10.14412/1995-4484-2009-589

36. Werner F., Wagner C., Simon M., Glatz K., Mertz K.D., Läubli H., Richtig E., Griss J., Wagner S.N. (2021). Loss of Lymphotoxin Alpha-Expressing Memory B Cells Correlates with Metastasis of Human Primary Melanoma. Diagnostics, 11 (7), 1238.

37. Yang D., Ud Din N., Browning D.D., Abrams S.I., & Liu K. (2007). Targeting lymphotoxin β receptor with tumor-specific T lymphocytes for tumor regression. Clinical cancer research, 13 (17), 5202-5210.

38. Dimitrakopoulos F.I.D., Kottorou A.E., Antonacopoulou A.G., Panagopoulos N., Scopa C., Kalofonou M., Dougenis D., Koutras A., Makatsortis T., Tzelepi V., Kalofonos H.P. (2019). Expression of immune system-related membrane receptors CD40, RANK, BAFFR and LTβR is associated with clinical outcome of operated non-small-cell lung cancer patients. Journal of clinical medicine, 8 (5), 741.

39. Conlon T.M., John-Schuster G., Heide D., Pfister D., Lehmann M., Hu Y., Ertüz Z., Lopez M.A., Ansari M., Strunz M., Mayr C., Ciminieri C., Costa R., Kohlhepp M.S., Guillot A., Günes G., Jeridi A., Funk M.C., Beroshvili G., Prokosch S., Hetzer J., Verleden S.E., Alsafadi H., Lindner M., Burgstaller G., Becker L., Irmler M., Dudek M., Janzen J., Goffin E., Gosens R., Knolle P., Pirotte B., Stoeger T., Beckers J., Wagner D., Singh I., Theis F.J., Hrabé de Angelis M., O’Connor T.O., Tacke F., Boutros M., Dejardin E., Eickelberg O., Schiller H.B., Königshoff M., Heikenwalder M., Yildirim A.Ö. (2020). Inhibition of LTβR signalling activates WNT-induced regeneration in lung. Nature, 588 (7836), 151-156.

40. Das R., Coupar J., Clavijo P.E., Saleh A., Cheng T.F., Yang X., Chen J., VanWaes C., Chen Z. (2019). Lymphotoxin‐β receptor‐NIK signaling induces alternative RELB/NF‐κB2 activation to promote metastatic gene expression and cell migration in head and neck cancer. Molecular carcinogenesis, 58 (3), 411-425.

41. Tang H., Zhu M., Qiao J., Fu Y.X. (2017). Lymphotoxin signalling in tertiary lymphoid structures and immunotherapy. Cellular & molecular immunology, 14(10), 809-818.

42. Buhrmann C., Kunnumakkara A.B., Popper B., Majeed M., Aggarwal B.B., Shakibaei M. (2020). Calebin A potentiates the effect of 5-FU and TNF-β (lymphotoxin α) against human colorectal cancer cells: potential role of NF-κB. International journal of molecular sciences, 21 (7), 2393.

43. Giles D.A., Zahner S., Krause P., Van Der Gracht E., Riffelmacher T., Morris V., Tumanov A., Kronenberg M. (2018). The tumor necrosis factor superfamily members TNFSF14 (LIGHT), lymphotoxin β and lymphotoxin β receptor interact to regulate intestinal inflammation. Frontiers in immunology, 9, 2585. doi: 10.3389/fimmu.2018.02585.

44. Buhrmann C., Yazdi M., Popper B., Shayan P., Goel A., Aggarwal B.B., Shakibaei M. (2018). Resveratrol chemosensitizes TNF-β-induced survival of 5-FU-treated colorectal cancer cells. Nutrients, 10 (7), 888. doi: 10.3390/nu10070888.

45. Buhrmann C., Popper B., Kunnumakkara A.B., Aggarwal B.B., Shakibaei M. (2019). Evidence that Calebin A, a component of curcuma longa suppresses NF-κB mediated proliferation, invasion and metastasis of human colorectal cancer induced by TNF-β (Lymphotoxin). Nutrients, 11 (12), 2904. doi: 10.3390/nu11122904.

46. Wang F.H., Wang Y., Sun G.P., Chen J.H., Lin Y.C., Liu W., Zheng R.S., Chen J., Zhang H.L., Lan H.T., Qi J., Liu Y.Q., Deng Y.M., Zhao H., Xiong J.P., Xu Q., Jiang W.Q., Li Y.H. (2017). Efficacy and safety of recombinant human lymphotoxin‐α derivative with cisplatin and fluorouracil in patients with metastatic esophageal squamous cell carcinoma: A randomized, multicenter, open‐label, controlled, phase 2b trial. Cancer, 123 (20), 3986-3994.

47. Yang J.G., Wang W.M., Xia H.F., Yu Z.L., Li H.M., Ren J.G., Chen G., Wang B.K., Jia J., Zhang W., Zhao Y.F. (2019). Lymphotoxin‐α promotes tumor angiogenesis in HNSCC by modulating glycolysis in a PFKFB3‐dependent manner. International journal of cancer, 145 (5), 1358-1370.

48. von Hoff L., Kärgel E., Franke V., McShane E., Schulz-Beiss K.W., Patone G., Schleussner N., Kolesnichenko M., Hübner N., Daumke O., Selbach M., Akalin A., Mathas S., Scheidereit C. (2019). Autocrine LTA signaling drives NF-κB and JAK-STAT activity and myeloid gene expression in Hodgkin lymphoma. Blood, The Journal of the American Society of Hematology, 133 (13), 1489-1494. doi: 10.1182/blood-2018-08-871293.


Review

For citations:


Garashchenko N.E., Seminskiy I.Zh. LYMPHOTOXIN ALPHA: BIOLOGICAL AND CLINICAL SIGNIFICANCE. Transbaikalian Medical Bulletin. 2022;(1):44-55. (In Russ.) https://doi.org/10.52485/19986173_2022_1_44

Views: 145


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1998-6173 (Online)